Please use this identifier to cite or link to this item:
|Title:||Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients|
Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.
Kaderli, Aysel Aydın
Gül, Özen Öz
Monocyte chemoattractant protein-1
Endocrinology & metabolism
|Citation:||Kıyıcı, S. vd. (2009). "Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients". Diabetes Research and Clinical Practice, 86(1), 44-50.|
|Abstract:||The aim of the study was to evaluate the long-term effect of rosiglitazone and metformin monotherapy with medical nutrition treatment (MNT) and of MNT alone on arterial stiffness, serum monocyte chemoattractant protein (MCP)-1 and matrix metalloproteinase (MMP)-9 in drug naive patients with type 2 diabetes mellitus. Fifty type 2 diabetic patients were randomized to receive rosiglitazone 4 mg/day (n = 19) or metformin 850 mg/day (n = 16) with MNT or MNT alone (n = 15), for 52 weeks. Arterial stiffness was assessed by using large and small artery elasticity index (SAEI and LAEI, respectively). SAEI, LAEI, serum MCP-1 and MMP-9 levels were measured at baseline and following 52 weeks of treatment. SAEI was improved only in the rosiglitazone group, and the difference was still statistically significant when the three groups were compared (p = 0.024). There were no differences in LAEI in inter- and intragroup comparisons at the end of the study. Serum MMP-9 levels were decreased in the metformin (-13.5 +/- 34.8%, p = 0.02) and rosiglitazone (-27.2 +/- 51.0%, p = 0.023) groups compared with baseline values, whereas no significant change was seen in serum MCP-1 levels. These results suggest that rosightazone monotherapy has favorable effects on arterial stiffness compared with metformin monotherapy independent of glycemic control.|
|Appears in Collections:||Scopus|
Web of Science
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.